Artemisinin Combination Therapy Market Outlook 2025–2035

The global Artemisinin Combination Therapy (ACT) Market is witnessing robust growth, fueled by global efforts to combat malaria, rising awareness of artemisinin resistance, and ongoing support from international health programs. According to recent data from Prophecy Market Insights, the Artemisinin Combination Therapy Market size was valued at USD 684.4 Million in 2025 and is expected to reach USD 1409.2 Million by 2035, expanding at a CAGR of 8.3% during the forecast period.

ACT has become the cornerstone of modern malaria treatment protocols, recommended by the World Health Organization (WHO) for the treatment of uncomplicated Plasmodium falciparum malaria, the most deadly form of the disease.

Sample Request: https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/5894

Market Segmentation

To provide a comprehensive understanding of market dynamics, the Artemisinin Combination Therapy market is segmented based on therapy type, end user, and region.

By Therapy Type:

• Artemether + Lumefantrine (AL)
  Widely used and among the most effective ACTs recommended for malaria-endemic regions.
• Artesunate + Amodiaquine (AS+AQ)
  A preferred combination in many African countries.
• Dihydroartemisinin + Piperaquine (DHA+PPQ)
  Offers long-acting protection and is favored in Southeast Asia.
• Artesunate + Mefloquine (AS+MQ)
  Frequently used in areas of multidrug resistance.
• Artesunate + Sulfadoxine-Pyrimethamine (AS+SP)
  Economical option but with limited use due to rising resistance.
• Pyronaridine-Artesunate
  A relatively newer ACT gaining regulatory and programmatic traction.
• Others
  Includes locally developed or pipeline combinations under development.

By End User:

• Hospitals
  Serve as primary centers for diagnosing and treating severe and uncomplicated malaria.
• Clinics
  Provide point-of-care treatment especially in suburban and rural areas.
• Government Health Facilities
  Operate national malaria control programs, particularly in high-burden countries.
• NGOs & International Health Organization Programs
  Major distributors of ACTs through subsidized and donor-funded campaigns.
• Others
  Includes private pharmacies and aid-based mobile clinics.

By Region:

• Africa: The largest market, accounting for the majority of malaria cases and ACT usage globally.
• Asia-Pacific: Key market due to the presence of artemisinin-resistant strains and concentrated malaria burden.
• Latin America: Relatively smaller but growing market, especially in the Amazon region.
• Middle East: Limited market size but still relevant due to migration and cross-border disease transmission.
• North America & Europe: Mainly for travel-related malaria treatments and research-based consumption.

Market Drivers

1. Global Malaria Elimination Initiatives

The WHO’s Global Technical Strategy for Malaria 2016–2030 aims to reduce malaria incidence and mortality by at least 90%. This initiative has led to increased procurement and distribution of ACTs in endemic regions through funding from organizations like the Global Fund, USAID’s PMI (President’s Malaria Initiative), and others.

2. Rise of Artemisinin Resistance

Southeast Asia has reported increasing resistance to monotherapy. This has created a strong case for adopting combination therapies with longer-acting partner drugs. DHA+PPQ and AS+MQ are preferred in resistant zones, creating regional market differentiation.

3. Increased Government and NGO Funding

Public-private partnerships are instrumental in making ACTs affordable and accessible. Donor agencies, government tenders, and NGO-driven programs have become the backbone of ACT supply chains in high-risk regions.

4. Regulatory Approvals and WHO Prequalification

Drugs prequalified by the WHO gain quicker adoption across multiple countries, reducing registration hurdles. This process promotes consistency and quality across national malaria control programs.

5. Innovation and New Combination Development

While ACTs are largely established, new fixed-dose combinations and pediatric formulations are under development to address resistance and improve patient compliance, especially among children.

PDF Request: https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/5894

Strategic Business and Investment Insights

For Pharmaceutical Companies:

The ACT market offers high-volume, program-driven opportunities with strong NGO and government support. Companies that align with WHO prequalification standards can access bulk procurement deals and international funding.

For Investors:

Investments in malaria-focused biopharma, diagnostics, and global health supply chains yield long-term impact and moderate return, particularly in ESG-focused portfolios. Opportunities also exist in scaling production of key ingredients like artemisinin APIs.

For Nonprofits and Global Health Organizations:

There is strong incentive to collaborate with manufacturers on technology transfers, licensing, and last-mile distribution strategies. Local manufacturing partnerships are also gaining traction in Africa and Asia.

Key Market Players

The ACT market is competitive, with both multinational corporations and regional players driving access and innovation.

Leading Companies:

• Novartis AG: Market leader with Coartem (Artemether + Lumefantrine), widely distributed globally.
• KPC Pharmaceuticals, Inc
• Shanghai Fosun Pharmaceutical Group Co., Ltd.
• Ajanta Pharma Ltd.
• Cipla
• Ipca Laboratories Ltd.
• NEM Laboratories
• Bliss GVS
• SHINPOONG.CO,.LTD
• Dr. Reddy’s Laboratories Ltd
• Manus Bio Inc.
• AdvaCare Pharma

These companies are involved in both bulk manufacturing and distribution partnerships with NGOs and health ministries.

Challenges

Resistance and Efficacy Concerns

The emergence of artemisinin-resistant Plasmodium strains necessitates continuous surveillance and the development of new combinations.

Supply Chain Volatility

Raw material procurement (especially artemisinin derived from Artemisia annua) is seasonal and subject to agricultural fluctuations, impacting production.

Pricing and Accessibility

ACT affordability remains a concern in many low-income countries where out-of-pocket expenditure is high. Even with donor support, supply chain gaps persist.

Recent Developments

• Novartis AG expanded its malaria portfolio with child-friendly ACT formulations in 2024 to improve pediatric compliance in sub-Saharan Africa.
• Ajanta Pharma received WHO prequalification for its DHA-Piperaquine combination, paving the way for broader international supply.
• Manus Bio Inc. is investing in biosynthetic artemisinin production to reduce cost and increase supply security.

Future Outlook and Opportunities

The Artemisinin Combination Therapy market is expected to remain mission-critical to global health goals. Innovations in combination therapies, surveillance programs, and diagnostics will shape its evolution through 2035. Further, there is increasing potential for local manufacturing partnerships, particularly in Africa and Southeast Asia, to ensure long-term sustainability.

Customization Request: https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/5894

Author:

Authored by Shweta R., Business Development Specialist at Prophecy Market Insights. This analysis is based on a combination of primary and secondary research, providing strategic insights into the evolving dynamics of the global Artemisinin Combination Therapy Market.